Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Obesity continues to grab attention at the JP Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback